Skip to content

Study · Randomized controlled trial · 2014

11 results

Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.

Becker RH, Stechl J, Msihid J, Kapitza C

Diabetes, obesity & metabolism25 Mar 2014Cited by 22 (Europe PMC)

PMID24521245 (opens in a new tab)PMCIDPMC4237545 (opens in a new tab)DOI10.1111/dom.12278 (opens in a new tab)PepBankPUB-24521245
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In people with type 2 diabetes in a randomized placebo-controlled crossover study, lixisenatide 20 µg increased first-phase insulin secretion 2.8-fold versus placebo, reaching rates comparable with healthy subjects on placebo.

    In plain wordsIn people with diabetes, lixisenatide raised early insulin release 2.8-fold versus placebo, to rates like healthy people on placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseFirst-phase insulin secretion in diabetes
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Measurements

    First-phase insulin secretion fold increase
    2.8 fold
    T2DM

    Source sentences

    Summary
    LIXI 20 µg reached maximum concentration after 2 h and resensitized first-phase insulin secretion by 2.8-fold in T2DM to rates comparable with those in HS on placebo, and raised second-phase insulin secretion by 1.6-fold in T2DM.
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.
  2. 02HumanRandomized controlled trialMechanism

    In people with type 2 diabetes in a randomized placebo-controlled crossover study, lixisenatide 20 µg increased second-phase insulin secretion 1.6-fold versus placebo.

    In plain wordsIn people with diabetes, lixisenatide raised later insulin release 1.6-fold versus placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSecond-phase insulin secretion in diabetes
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Second-phase insulin secretion fold increase
    1.6 fold
    T2DM

    Source sentences

    Summary
    LIXI 20 µg reached maximum concentration after 2 h and resensitized first-phase insulin secretion by 2.8-fold in T2DM to rates comparable with those in HS on placebo, and raised second-phase insulin secretion by 1.6-fold in T2DM.
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.
  3. 03HumanRandomized controlled trialMechanism

    In people with type 2 diabetes in a randomized placebo-controlled crossover study, insulin concentration rose correspondingly after lixisenatide 20 µg versus placebo.

    In plain wordsIn people with diabetes, insulin levels rose after lixisenatide versus placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseInsulin concentration in diabetes
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    INS rose correspondingly and glucose disposal was accelerated by 1.8-fold in T2DM.
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.
  4. 04HumanRandomized controlled trialMechanism

    In people with type 2 diabetes in a randomized placebo-controlled crossover study, lixisenatide 20 µg accelerated glucose disposal 1.8-fold versus placebo.

    In plain wordsIn people with diabetes, lixisenatide sped up blood sugar removal 1.8-fold versus placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseGlucose disposal in diabetes
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Glucose disposal fold increase
    1.8 fold
    T2DM

    Source sentences

    Summary
    INS rose correspondingly and glucose disposal was accelerated by 1.8-fold in T2DM.
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.
  5. 05HumanRandomized controlled trialMechanism

    In healthy subjects in a randomized placebo-controlled crossover study, lixisenatide 20 µg augmented first-phase insulin secretion versus placebo.

    In plain wordsIn healthy people, lixisenatide raised early insulin release versus placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseFirst-phase insulin secretion in healthy subjects
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    First-phase insulin secretion and glucose disposal were also augmented by LIXI in HS, whereas second-phase insulin secretion reduced blood glucose concentrations to below fasting levels and then ceased, accompanied by a rapid, short-lasting rise in glucagon.
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.
  6. 06HumanRandomized controlled trialMechanism

    In healthy subjects in a randomized placebo-controlled crossover study, lixisenatide 20 µg augmented glucose disposal versus placebo.

    In plain wordsIn healthy people, lixisenatide sped up blood sugar removal versus placebo.

    Peptide
    Lixisenatide
    Outcome
    IncreaseGlucose disposal in healthy subjects
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    First-phase insulin secretion and glucose disposal were also augmented by LIXI in HS, whereas second-phase insulin secretion reduced blood glucose concentrations to below fasting levels and then ceased, accompanied by a rapid, short-lasting rise in glucagon.
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.
  7. 07HumanNon-randomized trialPharmacokinetics

    In the healthy-subject and diabetes studies, lixisenatide reached maximum concentration after 2 h.

    In plain wordsIn the healthy-subject and diabetes studies, lixisenatide reached its highest concentration after 2 h.

    Peptide
    Lixisenatide
    Outcome
    Not applicableTime to maximum concentration
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Time to maximum concentration
    2 h
    lixisenatide 20 µg

    Source sentences

    Summary
    LIXI 20 µg reached maximum concentration after 2 h
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.
  8. 08HumanNon-randomized trialMechanism

    In healthy subjects after lixisenatide, second-phase insulin secretion reduced glucose below fasting levels and then ceased.

    In plain wordsIn healthy subjects after lixisenatide, later insulin release reduced blood sugar below fasting levels and then stopped.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGlucose below fasting levels in healthy subjects
    Study

    n: not reported in source

    Comparator
    Fasting glucose level
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    First-phase insulin secretion and glucose disposal were also augmented by LIXI in HS, whereas second-phase insulin secretion reduced blood glucose concentrations to below fasting levels and then ceased, accompanied by a rapid, short-lasting rise in glucagon.
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.
  9. 09HumanNon-randomized trialMechanism

    In healthy subjects after lixisenatide, a rapid, short-lasting glucagon rise accompanied glucose reduction below fasting levels.

    In plain wordsIn healthy subjects after lixisenatide, glucagon briefly increased as blood sugar decreased below fasting levels.

    Peptide
    Lixisenatide
    Outcome
    IncreaseCounter-regulatory glucagon rise in healthy subjects
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    First-phase insulin secretion and glucose disposal were also augmented by LIXI in HS, whereas second-phase insulin secretion reduced blood glucose concentrations to below fasting levels and then ceased, accompanied by a rapid, short-lasting rise in glucagon.
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.
  10. 10HumanNon-randomized trialMechanism

    In people with diabetes, lixisenatide otherwise left glucagon suppression after augmented insulin release unaffected.

    In plain wordsIn people with diabetes, lixisenatide otherwise did not change glucagon suppression after increased insulin release.

    Peptide
    Lixisenatide
    Outcome
    No significant changeGlucagon suppression in diabetes
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Otherwise, suppression of glucagon release subsequent to augmentation of insulin release was unaffected in T2DM and in HS.
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.
  11. 11HumanNon-randomized trialMechanism

    In healthy subjects, lixisenatide otherwise left glucagon suppression after augmented insulin release unaffected.

    In plain wordsIn healthy subjects, lixisenatide otherwise did not change glucagon suppression after increased insulin release.

    Peptide
    Lixisenatide
    Outcome
    No significant changeGlucagon suppression in healthy subjects
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Otherwise, suppression of glucagon release subsequent to augmentation of insulin release was unaffected in T2DM and in HS.
    2 context sentences
    Summary · context
    Two single-centre, double-blind, randomized, placebo-controlled, single-dose, crossover studies were performed in healthy subjects (HS) and people with type 2 diabetes mellitus (T2DM).
    Summary · context
    Participants received subcutaneous LIXI or placebo 2 h before an iv glucose challenge.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.